Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Sauzullo, Ilaria ^a   Scrivo, Rossana ^b   Sessa, Paola ^b   Mengoni, Fabio ^a   Vullo, Vincenzo ^a   Valesini, Guido ^b   Mastroianni, Claudio Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD134 ANTIGEN; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGENIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC DISEASE; CYTOLOGY; DRUG EFFECT; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE;

ADALIMUMAB; ADULT; AGED; ARTHRITIS, PSORIATIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHRONIC DISEASE; ETANERCEPT; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MITOGENS; RECEPTORS, OX40; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85047270568     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-26097-x     Document Type: Article

References (44)

1. Brennan, F. M. et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).
2. Choo-Kang, B. S. et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol 26, 518-522 (2005).
3. Feldmann, M. et al. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 19, 163-196 (2001).
4. Pang, L. et al. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J Rheumatol 35, 2220-2228 (2008).
5. Ogata, A. et al. Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol 20, 130-133 (2010).
6. Amital, H. et al. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann N Y Acad Sci 1110, 649-660 (2007).
7. Giardina, A. R. et al. Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? Reumatismo 61, 21-26 (2009).
8. Agnothlt, J. et al. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23, 76-85 (2003).
9. Hamdi, H. et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8, R114 (2006).
10. Popa, C. et al. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur Cytokine Netw 20, 88-93 (2009).
11. Saliu, O. Y. et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194, 486-492 (2006).
12. Zou, J. et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 62, 561-564 (2003).
13. Bosè, F. al. Dual role of anti-TNF therapy enhances TCR-mediated T cell activation and inhibits inflammation. Clin Immunol 139, 164-176 (2011).
14. Mazurek, G. H. et al. Division of tuberculosis elimination, national center for HIV, STD, and TB prevention, CDC. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection. MMWR 59(RR05), 1-25 (2010).
15. Taggart, E. W. et al. Evaluation of an in vitro assay for gamma interferon production in response to Mycobacterium tuberculosis infections. Clin Diagn Lab Immunol 11, 1089-1093 (2004).
16. Wong, S. H. et al. Effect of immunosuppressive therapy on interferon ? release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 71, 64-72 (2016).
17. Arias-Guillen, M. et al. T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 20, 329-338 (2014).
18. Bartalesi, F. et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33, 586-593 (2009).
19. Matulis, G. et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67, 84-90 (2008).
20. Papay, P. et al. Factors impacting the results of interferon-? release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 17, 84-90 (2011).
21. Wong, S. H. et al. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients. Inflamm Bowel Dis 20, 2067-2072 (2014).
22. Scrivo, R. et al. Mycobacterial interferon-? release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 40, 157-165 (2013).
23. Sauzullo, I. et al. Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists. Clin Exp Immunol 176, 410-417 (2014).
24. Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44-48 (1995).
25. Mannering, S. I. et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods 283, 173-183 (2003).
26. Enbrel prescribing information. Thousand Oaks, CA, and Madison, NJ: Amgen and Wyeth Pharmaceuticals, 2005. Available at: http://www. enbrel. com/prescribing-information. jsp (2006).
27. Humira prescribing information. Abbott Park, IL: Abbott Laboratories, 2005. Available at: http://www. rxabbott. com/pdf/humira. pdf (2006).
28. Arnett, F. C. et al. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-324 (1988).
29. Taylor, W. et al. CASPAR Study Group. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 54, 2665-2673 (2006).
30. Aravena, O. et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-?-producing NK cell and regulatory T cell subsets. Immunobiology 216, 1256-1263 (2011).
31. Cope, A. P. et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94, 749-760 (1994).
32. Baeten, D. et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFa. Ann Rheum Dis 60, 750-755 (2001).
33. Schuerwegh, A. J. et al. Influence of therapy with chimeric monoclonal tumor necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology 42, 541-548 (2003).
34. Berg, L. et al. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF? receptors. Ann Rheum Dis 60, 133-139 (2001).
35. Zaunders, J. J. et al. High levels of human antigen-specific CD4 T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 183, 2827-2836 (2009).
36. Croft, M. Co-stimulatory members of the TNFR family: keys to effective T cell immunity? Nat Rev Immunol 3, 609-620 (2003).
37. Lenardo, M. et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Ann Rev Immunol 17, 21-53 (1999).
38. Zou, J. et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 48, 780-790 (2003).
39. Vigna-Pérez, M. et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 141, 372-380 (2005).
40. Kavanaugh, A. F. et al. Treatment with adalimumab (D2E7) does not affect normal immune responsiveness. Arthritis Rheum 46, S132 (2002).
41. Moreland, L. W. et al. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 103, 13-21 (2002).
42. Aaltonen, K. J. et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 42, 372-378 (2015).
43. Morgan, C. L. et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 53, 186-194 (2014).
44. van Assen, S. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70, 414-422 (2011).